Bone marrow microenvironment in multiple myeloma progression

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Manier, S ^a,b   Sacco, A ^a   Leleu, X ^b   Ghobrial, I M ^a   Roccaro, A M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; COLLAGEN TYPE 1; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MYC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL XL; PROTEIN MCL 1; SCATTER FACTOR; SOMATOMEDIN C; STAT3 PROTEIN; SYNDECAN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VERY LATE ACTIVATION ANTIGEN 4; CYTOKINE;

APOPTOSIS; BONE MARROW; BONE REMODELING; CANCER PROGNOSIS; CELL ACTIVATION; CELL ADHESION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL HOMING; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CYTOKINE RELEASE; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; MULTIPLE MYELOMA; OSTEOBLAST; PLASMA CELL; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL NICHE; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WNT SIGNALING PATHWAY; ANIMAL; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGY;

ANIMALS; BONE MARROW; CYTOKINES; HUMANS; MODELS, IMMUNOLOGICAL; MULTIPLE MYELOMA;

EID: 84871913165     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/157496     Document Type: Review

References (46)

1. Kyle R. A., Rajkumar S. V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple Myeloma. Leukemia 2009 23 1 3 9 2-s2.0-58249097191 10.1038/leu.2008.291
2. Landgren O., Kyle R. A., Pfeiffer R. M., Katzmann J. A., Caporaso N. E., Hayes R. B., Dispenzieri A., Kumar S., Clark R. J., Baris D., Hoover R., Rajkumar S. V., Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple Myeloma: a prospective study. Blood 2009 113 22 5412 5417 2-s2.0-67049162188 10.1182/blood-2008-12-194241
3. Weiss B. M., Abadie J., Verma P., Howard R. S., Kuehl W. M., A monoclonal gammopathy precedes multiple Myeloma in most patients. Blood 2009 113 22 5418 5422 2-s2.0-67049114114 10.1182/blood-2008-12-195008
4. Kyle R. A., Durie B. G., Rajkumar S. V., Landgren O., Blade J., Merlini G., Kröger N., Einsele H., Vesole D. H., Dimopoulos M., San Miguel J., Avet-Loiseau H., Hajek R., Chen W. M., Anderson K. C., Ludwig H., Sonneveld P., Pavlovsky S., Palumbo A., Richardson P. G., Barlogie B., Greipp P., Vescio R., Turesson I., Westin J., Boccadoro M., International Myeloma Working Group, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple Myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010 24 6 1121 1127 2-s2.0-77954610729
5. Bergsagel P. L., Kuehl W. M., Zhan F., Sawyer J., Barlogie B., Shaughnessy J. Jr., Cyclin D dysregulation: an early and unifying pathogenic event in multiple Myeloma. Blood 2005 106 1 296 303 2-s2.0-22044440425 10.1182/blood-2005-01-0034 (Pubitemid 40967205)
6. Korde N., Kristinsson S. Y., Landgren O., Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple Myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011 117 21 5573 5581 2-s2.0-79957585619 10.1182/blood-2011-01-270140
7. Ghobrial I. M., Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012 120 1 20 30
8. Fidler I. J., The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nature Reviews Cancer 2003 3 6 453 458 2-s2.0-0038481970 10.1038/nrc1098 (Pubitemid 37328849)
9. Hideshima T., Bergsagel P. L., Kuehl W. M., Anderson K. C., Advances in biology of multiple Myeloma: clinical applications. Blood 2004 104 3 607 618 2-s2.0-3242777803 10.1182/blood-2004-01-0037 (Pubitemid 38970551)
10. Kumar S., Witzig T. E., Timm M., Haug J., Wellik L., Fonseca R., Greipp P. R., Rajkumar S. V., Expression of VEGF and its receptors by Myeloma cells. Leukemia 2003 17 10 2025 2031 2-s2.0-0142151228 10.1038/sj.leu.2403084 (Pubitemid 37322133)
11. Radtke F., Raj K., The role of Notch in tumorigenesis: oncogene or tumour suppressor. Nature Reviews Cancer 2003 3 10 756 767 2-s2.0-0142259346 (Pubitemid 37328814)
12. Nefedova Y., Cheng P., Alsina M., Dalton W. S., Gabrilovich D. I., Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of Myeloma and other malignant lymphoid cell lines. Blood 2004 103 9 3503 3510 2-s2.0-1942425110 10.1182/blood-2003-07-2340 (Pubitemid 38525684)
13. Giuliani N., Storti P., Bolzoni M., Palma B. D., Bonomini S., Angiogenesis and multiple Myeloma. Cancer Microenvironment 2011 4 3 325 337 2-s2.0-79959837077 10.1007/s12307-011-0072-9
14. Roccaro A. M., Sacco A., Azab A. K., Stroma-derived exosomes mediate oncogenesis in multiple Myeloma. Blood 2011 118, abstract 625. ASH Annual Meeting Abstracts
15. Podar K., Anderson K. C., The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005 105 4 1383 1395 2-s2.0-13544255403 10.1182/blood-2004-07-2909 (Pubitemid 40223651)
16. Rajkumar S. V., Witzig T. E., A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple Myeloma. Cancer Treatment Reviews 2000 26 5 351 362 2-s2.0-0033785490 10.1053/ctrv.2000.0188
17. Kumar S., Gertz M. A., Dispenzieri A., Lacy M. Q., Wellik L. A., Fonseca R., Lust J. A., Witzig T. E., Kyle R. A., Greipp P. R., Rajkumar S. V., Prognostic value of bone marrow angiogenesis in patients with multiple Myeloma undergoing high-dose therapy. Bone Marrow Transplantation 2004 34 3 235 239 2-s2.0-4344640371 10.1038/sj.bmt.1704555 (Pubitemid 39136830)
18. Ria R., Todoerti K., Berardi S., Coluccia A. M. L., De Luisi A., Mattioli M., Ronchetti D., Morabito F., Guarini A., Petrucci M. T., Dammacco F., Ribatti D., Neri A., Vacca A., Gene expression profiling of bone marrow endothelial cells in patients with multiple Myeloma. Clinical Cancer Research 2009 15 17 5369 5378 2-s2.0-69949084408 10.1158/1078-0432.CCR-09-0040
19. Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., Alexandre C., Mechanisms of bone destruction in multiple Myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology 1989 7 12 1909 1914 2-s2.0-0024786736 (Pubitemid 20014340)
20. Roodman G. D., Pathogenesis of Myeloma bone disease. Leukemia 2009 23 3 435 441 2-s2.0-62549117773 10.1038/leu.2008.336
21. Ehrlich L. A., Roodman G. D., The role of immune cells and inflammatory cytokines in Paget's disease and multiple Myeloma. Immunological Reviews 2005 208 252 266 2-s2.0-28544437394 (Pubitemid 41746397)
22. Yaccoby S., Pearse R. N., Johnson C. L., Barlogie B., Choi Y., Epstein J., Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology 2002 116 2 278 290 2-s2.0-0036181668 10.1046/j.1365-2141.2002.03257. x (Pubitemid 34156975)
23. Tanaka Y., Abe M., Hiasa M., Oda A., Amou H., Nakano A., Takeuchi K., Kitazoe K., Kido S., Inoue D., Moriyama K., Hashimoto T., Ozaki S., Matsumoto T., Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clinical Cancer Research 2007 13 3 816 823 2-s2.0-33847368961 10.1158/1078-0432.CCR-06-2258 (Pubitemid 46340354)
24. Karadag A., Oyajobi B. O., Apperley J. F., Graham R., Russell G., Croucher P. I., Human Myeloma cells promote the production of interleukin 6 by primary human osteoblasts. British Journal of Haematology 2000 108 2 383 390 2-s2.0-0034012201 10.1046/j.1365-2141.2000.01845.x (Pubitemid 30143655)
25. Shipman C. M., Croucher P. I., Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human Myeloma cells. Cancer Research 2003 63 5 912 916 2-s2.0-0037374460 (Pubitemid 36278418)
26. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J. D. Jr., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple Myeloma. The New England Journal of Medicine 2003 349 26 2483 2494 2-s2.0-0346363760 10.1056/NEJMoa030847 (Pubitemid 38010074)
27. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J. D. Jr., Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple Myeloma growth in vivo. Blood 2007 109 5 2106 2111 2-s2.0-33847397091 10.1182/blood-2006-09-047712 (Pubitemid 46348212)
28. Edwards C. M., Edwards J. R., Lwin S. T., Esparza J., Oyajobi B. O., McCluskey B., Munoz S., Grubbs B., Mundy G. R., Increasing wnt signaling in the bone marrow microenvironment inhibits the development of Myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008 111 5 2833 2842 2-s2.0-41949093576 10.1182/blood-2007-03-077685
29. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S. A., Shen Z., Patel N., Tai Y. T., Chauhan D., Mitsiades C., Prabhala R., Raje N., Anderson K. C., Stover D. R., Munshi N. C., Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple Myeloma. Blood 2009 114 2 371 379 2-s2.0-67650431302 10.1182/blood-2008-11-191577
30. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T., Autocrine generation and requirement of BSF-2/IL-6 for human multiple Myelomas. Nature 1988 332 6159 83 85 2-s2.0-0023849455
31. Hideshima T., Nakamura N., Chauhan D., Anderson K. C., Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple Myeloma. Oncogene 2001 20 42 5991 6000 2-s2.0-0035921689 10.1038/sj.onc.1204833 (Pubitemid 32955041)
32. Dinarello C. A., Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011 117 14 3720 3732 2-s2.0-79953813107 10.1182/blood-2010-07-273417
33. Chauhan D., Kharbanda S., Ogata A., Urashima M., Teoh G., Robertson M., Kufe D. W., Anderson K. C., Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple Myeloma cells. Blood 1997 89 1 227 234 2-s2.0-0031029911 (Pubitemid 26428197)
34. Hideshima T., Mitsiades C., Tonon G., Richardson P. G., Anderson K. C., Understanding multiple Myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer 2007 7 8 585 598 2-s2.0-34547106018 10.1038/nrc2189 (Pubitemid 47106630)
35. Ludwig H., Nachbaur D. M., Fritz E., Krainer M., Huber H., Interleukin-6 is a prognostic factor in multiple Myeloma. Blood 1991 77 12 2794 2795 2-s2.0-0025875857
36. Lust J. A., Lacy M. Q., Zeldenrust S. R., Dispenzieri A., Gertz M. A., Witzig T. E., Kumar S., Hayman S. R., Russell S. J., Buadi F. K., Geyer S. M., Campbell M. E., Kyle R. A., Rajkumar S. V., Greipp P. R., Kline M. P., Xiong Y., Moon-Tasson L. L., Donovan K. A., Induction of a chronic disease state in patients with smoldering or indolent multiple Myeloma by targeting interleukin 1 β -induced interleukin 6 production and the Myeloma proliferative component. Mayo Clinic Proceedings 2009 84 2 114 122 2-s2.0-61449122079 10.4065/84.2.114
37. Pollak M., Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer 2008 8 12 915 928 2-s2.0-56749184290 10.1038/nrc2536
38. De Bruyne E., Bos T. J., Schuit F., Van Valckenborgh E., Menu E., Thorrez L., Atadja P., Jernberg-Wiklund H., Vanderkerken K., IGF-1 suppresses Bim expression in multiple Myeloma via epigenetic and posttranslational mechanisms. Blood 2010 115 12 2430 2440 2-s2.0-77950556094 10.1182/blood-2009-07-232801
39. Nowakowski G. S., Witzig T. E., Dingli D., Tracz M. J., Gertz M. A., Lacy M. Q., Lust J. A., Dispenzieri A., Greipp P. R., Kyle R. A., Rajkumar S. V., Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple Myeloma. Blood 2005 106 7 2276 2279 2-s2.0-27144493396 10.1182/blood-2005-05-1858 (Pubitemid 41510796)
40. Sanz-Rodríguez F., Hidalgo A., Teixidó J., Chemokine stromal cell-derived factor-1 α modulates VLA-4 integrin-mediated multiple Myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001 97 2 346 351 2-s2.0-0035863789 10.1182/blood.V97.2.346 (Pubitemid 32060316)
41. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U. K., Pitsillides C. M., Spencer J. A., Kimlinger T., Ghobrial J. M., Jia X., Lu G., Timm M., Kumar A., Côté D., Veilleux I., Hedin K. E., Roodman G. D., Witzig T. E., Kung A. L., Hideshima T., Anderson K. C., Lin C. P., Ghobrial I. M., Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple Myeloma. Blood 2007 109 7 2708 2717 2-s2.0-33947600329 10.1182/blood-2006-07-035857 (Pubitemid 46482062)
42. Lapidot T., Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice: the role of SDF-1/CXCR4 interactions. Annals of the New York Academy of Sciences 2001 938 83 95 2-s2.0-0034932187 (Pubitemid 32620021)
43. Cipolleschi M. G., Sbarba P. D., Olivotto M., The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 1993 82 7 2031 2037 2-s2.0-0027443181 (Pubitemid 23293984)
44. Kaplan R. N., Riba R. D., Zacharoulis S., Bramley A. H., Vincent L., Costa C., MacDonald D. D., Jin D. K., Shido K., Kerns S. A., Zhu Z., Hicklin D., Wu Y., Port J. L., Altorki N., Port E. R., Ruggero D., Shmelkov S. V., Jensen K. K., Rafii S., Lyden D., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005 438 7069 820 827 2-s2.0-28644432204 10.1038/nature04186 (Pubitemid 41753060)
45. Psaila B., Lyden D., The metastatic niche: adapting the foreign soil. Nature Reviews Cancer 2009 9 4 285 293 2-s2.0-63049121364 10.1038/nrc2621
46. Peinado H., Aleckovic M., Lavotshkin S., Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine 2012 18 6 883 891